Trabectedin in the treatment of soft tissue sarcoma: Real‐world data on effectiveness, safety, and financial implications from a European comprehensive cancer center

Authors:

Abstract
Soft‐tissue sarcomas (STS) comprise over 150 histological subtypes, with advanced cases showing poor prognosis (5‐year survival n = 16), soft‐tissue leiomyosarcomas ( n = 17), and myxoid liposarcomas ( n = 8). Non‐L‐sarcomas (22%) included mostly synovial sarcomas. The overall disease control rate was 71%, with a median progression‐free survival (PFS) of 4.1 months, and an overall survival of 12.3 months. Subtype‐specific median PFS was 6.8 months for liposarcomas (11.3 for myxoid vs. 4.5 for other subtypes), 3.1 months for leiomyosarcomas (3.4 months for uterine vs. 3.1 for soft‐tissue), and 2.4 months for non‐L‐sarcomas. Patients received a median of 5 cycles (range: 1–38), with an average total dose of 16 mg [2–81], and an average hospital cost of €9900. Adverse events occurred in 91%, mainly hematological; cardiac toxicity was seen in 9%. This retrospective single‐center study in a limited cohort provides real‐world insights but should be interpreted with caution. Despite limited reimbursement, trabectedin may retain clinical utility, particularly in L‐sarcoma management.

This publication has 28 references indexed in Scilit: